AZ’s Fasenra shows promise in hypereosinophilic syndrome
The drug is AstraZeneca’s first respiratory biologic.
Read More
Tag: hypereosinophilic syndrome
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
